US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Capricor Therapeutics Inc (CAPR)
Capricor Therapeutics Inc (CAPR) ニュース

Capricor Therapeutics Inc (CAPR)

25.04

-0.29

(-1.14%)

終値： 6月12日 5:00AM

25.04

0.00

( 0.00% )

取引時間後: 8:30AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Form 8-K - Current report

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144/A - Report of proposed sale of securities: [Amend]

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE...

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

ed3/6me

ed3/6me 2週前

Think it will peek at 40 again this time

Topfuel

Topfuel 2週前

Got a few been flipping was in on last big run

ed3/6me

ed3/6me 2週前

Grab some or regret soon

ed3/6me

ed3/6me 2週前

Am not complaining but had been timing ups and owns great here. Was a little off this time

ed3/6me

ed3/6me 3週前

Something is brewing

dia76ca

dia76ca 4週前

Deramiocel approval + Capricor markets in US = $100+

ed3/6me

ed3/6me 4週前

Read between the lines in their suit.

ed3/6me

ed3/6me 4週前

Thank you for upping my count here everyone who sold today

ed3/6me

ed3/6me 1月前

take advantage while low!! i did

👍️ 1 💯 1

ed3/6me

ed3/6me 1月前

What shook other people out took me back

Zardiw

Really nice $CAPR Article:

https://talkmarkets.com/article/capricors-pdufa-on-deramiocel-offers-excellent-risk-reward-for-august-expiration-1776703236

Z

dia76ca

dia76ca 2月前

1-Year Return
CAPR
252.23%
S&P 500
33.02%

3-Year Return
CAPR
675.23%
S&P 500
69.60%

5-Year Return
CAPR
746.76%
S&P 500
67.67%

ed3/6me

ed3/6me 2月前

dia76ca

dia76ca 2月前

There are a series of BIG catalysts coming... starting within the next few weeks or months!
* The FDA approval of Deramiocel for DMD can happen at any time. The PDUFA date of Aug.22 has been set, so approvals can come any day before then. This will trigger hundreds of millions in milestones and a large voucher (worth about $200 million)
* A large European partnership for Deramiocel is expected to follow. This will again spark hundreds of millions in milestones. Will it be with Nippon Shinyaku (NS) or with a Big Pharma?
* Deramiocel entry into the Japanese market with NS will soon follow with more milestones.
* Sales of Deramiocel for DMD in the US will occur soon after approval. NS already has a sales force in place and Capricor has stockpiled doses for 150 patients. By the end of 2027 they expect to serve over 3,000 patients.
* There will be updates later this year about "several" StealthX exosome delivered therapeutics ready for IND's in 2027. This is in addition to any further vaccine trials likely to continue to be funded by NIAID.
* Capricor already has $300 million in cash and no debt. Lots of catalysts and lots of cash coming soon!

ed3/6me

ed3/6me 2月前

All the people touting this... When will it kick in?

dia76ca

dia76ca 2月前

Absolutley! I will hold all my Capricor shares until the buy-out. In 3 or 4 years the cardiomyopathy platform and the StealthX exosome drug delivery platform should be worth many billions. Capricor is cash rich now but will be even richer when Deramiocel is approved. And I look forward to 3 or 4 StealthX therapeutic exosome IND's in 2027.

ed3/6me

ed3/6me 2月前

Enthapy. Still here?

dia76ca

dia76ca 2月前

Catalyst rich! Cash rich! Do your own dd !
1. With August 22 PDUFA date Deramiocel FDA approval can come any day!
2. Phase 3 data article in medical journal
3. Latest Share Price targets by analysts now $60-+
4. Deramiocel European + ROW PARTNERSHIP (with NS or Big Pharma ?) Upfront/ Milestones likely $1 Billion plus!
5. NS milestones for Deramiocel in Japan
6. Becker will advance (approval or trial)
7. StealthX Covid vaccine trial(NIAID funded) likely to continue.
8. Several (3+) StealthX Therapeutics IND's in 2027
9. US earnings in 2026
10. Clean rooms added.
11. Quarterly Report updates
12. Buyout chatter!
Capricor is cash rich with $300 million cash: $80 million NS milestone on US approval and a PRV worth about $200 million ,$605 million US milestones+ new partner upfronts and milestones ! ( $2 + Billion milestones and cash?). NICE!

ed3/6me

ed3/6me 2月前

Probably those who get cheap shares as pay.

MyFiveCents

MyFiveCents 2月前

I see several insiders just sold bunch of shares.
Do they know something that we don't?

ed3/6me

ed3/6me 3月前

Am tired of being poor.... Let's go!

ed3/6me

ed3/6me 3月前

love ping pong. a few more shares from waffling and am back here again

ed3/6me

ed3/6me 3月前

The market touts it too as the mark is now raised from 50 to 63

dia76ca

dia76ca 3月前

If you have not seen it before, have a look at the slides of Dr. Craig McDonald's presentation of the phase 3 data at the recent MDA Conference.
The data is strong!
https://d1io3yog0oux5.cloudfront.net/_5b99e26ce1ff49eed4f7d3b537a39b87/capricor/db/2227/21507/pdf/MDA+2026+CAPR+3.11.26+late-breaker.pdf

ed3/6me

ed3/6me 3月前

Get a boost on value and watch it go down

D-bol

Going to be fun this week

dia76ca

dia76ca 4月前

Submission Complete! Oral Presentation at Conference March 11 ! And then...
1. Phase 3 data article published in leading medical journal
2. FDA announcing new PDUFA date
3. Deramiocel FDA approval
4. Deramiocel European + ROW PARTNERSHIP
(with NS or Big Pharma ?)
5. More NS milestones for Deramiocel in Japan
6. Becker will advance (approval or trial)
7. StealthX Covid vaccine results (NIAID funded)
8. StealthX Big Pharma and/or more NIAID PARTNERSHIP(s)
9. Deramiocel US earnings in 2026
10. More Analysts
11. Quarterly Report updates
12. Increased Share Price Targets by Analysts
Followed by increased chatter about buyout !

Meanwhile Capricor is cash rich with some $330 million cash; an $80 million NS milestone upon US approval and a PRV worth as much as $200 million ,$605 million sales milestones+ new partnership upfronts and milestones !

dia76ca

dia76ca 4月前

I think it is a certainty that Capricor will be bought out at some time in the next few years!
Deramiocel alone makes it a great addition to a Big Pharm pipeline. DMD, Becker and other
cardiomyopathies will provide a large and growing revenue stream beginning in 2026!

The StealthX exosome platform drug delivery has an even larger potential. Capricor has
several vaccines ready for the clinic right now! And there scores of Therapeutic applications
including rare diseases, oncology and inflammatory diseases. IMO StealthX revenues will
exceed those of Deramiocel!

And the Marban Labs at Cedars-Sinai have come up with an amazing drug in TY1. It is
ready to go into the clinic and its many applications will make it a Super-Blockbuster!
I see an upcoming bidding war for Capricor. Great Science! Great Future!

XWAVXALMIMAN

XWAVXALMIMAN 4月前

Nice move today. How high can we go? Do you think a larger company might buy us?

dia76ca

dia76ca 4月前

Submission over soon! Then...
1. Phase 3 data article published in leading medical journal
2. FDA announcing new PDUFA date
3. Deramiocel FDA approval
4. Deramiocel European + ROW PARTNERSHIP
(with NS or Big Pharma ?)
5. More NS milestones for Deramiocel in Japan
6. Becker will advance (approval or trial)
7. StealthX Covid vaccine results (NIAID funded)
8. StealthX Big Pharma and/or more NIAID PARTNERSHIP(s)
9. Deramiocel US earnings in 2026
10. More Analysts
11. Quarterly Report updates
12. Increased Share Price Targets by Analysts
13. TY1 from Marban Labs enters clinic
14. Increased chatter about buyout !
Capricor is cash rich with some $330 million cash; an $80 million NS milestone upon US approval and a PRV worth as much as $200 million ,$605 million sales milestones+ new partnership upfronts and milestones !
Nice to be long!

XWAVXALMIMAN

XWAVXALMIMAN 4月前

Ed, try XRP. I’m down from 40,000 CAPR to 15,000. I still have confidence in CAPR but I have sold between 25-31 and buy 15-30,000 XRP by selling 1-2000 CAPR. I think both will double but XRP will easily triple .

ed3/6me

ed3/6me 4月前

In again. Only play I'm in making money

dia76ca

dia76ca 4月前

New Corporate Presentation. Great read!
https://d1io3yog0oux5.cloudfront.net/_fc552ab0de70aea3033355e9b059d762/capricor/db/2227/21490/pdf/CAPR+Feb+2026+%28Corporate+Deck%29.pdf

ed3/6me

ed3/6me 4月前

so does tang own 13% or 19%?

ed3/6me

ed3/6me 5月前

Hope there's good news in morning

dia76ca

dia76ca 5月前

The BIOTECH TV presentation by Linda Marban on TUESDAY January 13, 2026 could be very important. I don't know if it is the same people that did the Bio Tech Health X presentation on August 9 2024 but Linda got a lot of information across in 22 minutes!
https://www.bing.com/videos/riverview/relatedvideo?q=biotech+tv+jan.13+2026+linda+marban&cvid=d720dcadb7bd433c8c271918b2edf677&gs_lcrp=EgRlZGdlKgYIABBFGDkyBggAEEUYOTIGCAEQABhAMgYIAhAAGEDSAQk0NzE1M2owajSoAgiwAgE&adppc=EDGEESS&PC=ACTS&ru=%2fsearch%3fq%3dbiotech%2btv%2bjan.13%2b2026%2blinda%2bmarban%26cvid%3dd720dcadb7bd433c8c271918b2edf677%26gs_lcrp%3dEgRlZGdlKgYIABBFGDkyBggAEEUYOTIGCAEQABhAMgYIAhAAGEDSAQk0NzE1M2owajSoAgiwAgE%26FORM%3dANAB01%26adppc%3dEDGEESS%26PC%3dACTS&mmscn=vwrc&mid=E34311F4A25E1221E979E34311F4A25E1221E979&FORM=WRVORC&ntb=1&msockid=9c291325ef0411f0900cab89376f4f32

ed3/6me

ed3/6me 5月前

lets get it on now. love me some news....please

dia76ca

dia76ca 5月前

What does Capricor's financial situation look like in 2026?
* It has about $300 million cash on hand.
* With Deramiocel approval it will receive $80 million from a NS milestone and a PRV worth at least $150 million.
* They have hundreds of millions due in upfront and milestones from NS when Deramiocel is advanced in Japan.
* There will be hundreds of millions due in upfront and milestones when they sign an European/ROW partnership with NS or a Big Pharma.
* There will be Deramiocel revenue in the US beginning in 2026. And there will be sales milestones from NS !
* They have said that they intend to partner the exosome based products from the StealthX PLATFORM. Will they have many partners with many products? Or will there be one large partnership with Big Pharma ?
Either way there will be upfront, milestone and royalty revenues starting in 2026.
CAPRICOR has a solid financial base in 2026. And it will only get stronger year after year.

dia76ca

dia76ca 5月前

2026 is the pivotal year for Capricor!
There should be 6 big 2026 catalysts...
1. Deramiocel FDA approval
2. Deramiocel European + ROW PARTNERSHIP
3. Becker will be advanced (approval or trial)
4. StealthX Covid vaccine results
5. StealthX BP and NIAID PARTNERSHIP(s)
6. Deramiocel US earnings in 2026
Capricor is already CASH RICH and another $80 million will come with Deramiocel approval as will a PRV which recently have been sold for over $150 million. And Deramiocel and StealthX PARTNERSHIP(s) will bring upfront, milestone and royalty payments !
All these catalysts will dramatically increase the share price. A partnership/buyout similar to Genentech is possible in the next few years. Capricor is the new Genentech of the Exosome world IMO. Great 2026 for all patients and investors!

dia76ca

dia76ca 6月前

Register for this event if you want an update on Wednesday, Dec. 17 at 1pm ET. Just scroll down to get the registration information.
https://www.parentprojectmd.org/events/

XWAVXALMIMAN

XWAVXALMIMAN 6月前

I had trouble selling at 35 and ended up selling some at 25 and then 30 and sold a little more at 28. I had 38,000 for many years buying in 2020-2021 at 3-5. I’m down to 23,000 shares now and plan to hold but I don’t trust RFK and FDA. I hope we get approval but what if they say it is too expensive?
When does everyone think we will get an answer from FDA? I’ll try to check here more regularly.

dia76ca

dia76ca 6月前

Here Linda explains how Deramiocel works in under 7 minutes. Well worth a listen !
https://www.cgtlive.com/view/marban-evaluating-capricor-cardiomyopathy-cell-therapy-deramiocel-dmd

dia76ca

dia76ca 6月前

I agree with those who think the BLA submission to the FDA could happen before the end of this year. That news alone could take the share price to around $40.
But what will happen in 2026?
There should be 5 big 2026 catalysts...
1. Deramiocel FDA approval
2. Deramiocel European + ROW partnership
3. StealthX vaccine results
4. StealthX BP and NIAID partnership(s)
5. Deramiocel US earnings in 2026
Capricor is already CASH RICH and another $80 million will come with approval as will a PRV which recently have been sold for over $150 million.
Good partnerships could bring the share price up to the $200 range IMO. But it could be bought out for much more at any time.

dia76ca

dia76ca 6月前

Just imagine for a moment that you are an executive of a Big Pharma. The patents on your best selling drugs are expiring. You need to refill the pipeline.
What are you looking for? It would be nice to have some instant revenue. It would also be nice to have an entire platform to produce new drugs year after year.
What does Capricor offer? It has Deramiocel revenues starting about mid-year 2026. It also has the StealthX exosome platform with the first of many potential clinical trials reporting in early 2026.
Pfizer, Roche and many other Big Pharmas are in exactly the same position. Partnership or partnership/buyout discussions can take many months. But they will take place! And Cash Rich Capricor is in the drivers seat !

bikaver

bikaver 6月前

CAPR.....Took some 25.50's. Looking for another push next week.

cmcclos1

cmcclos1 6月前

$483 just nov 6

dia76ca

dia76ca 6月前

We know Pfizer, Novartis and Roche all need to fill their depleted pipelines. And they would all like to receive cash flow as soon as possible. But they are also looking for long term platforms to produce many drugs.

And they all know about Capricor. It will produce cash flow in 2026 with its Deramiocel sales.
And it has the StealthX exosome platform which can become the world leading delivery system for both vaccines and therapeutics.

Would Pfizer , Novartis or Roche like to partner with Capricor? Certainly they would! But would they prefer to do a buyout? Probably. Certainly they do not want Deramiocel and StealthX to fall into the hands of their competition! Do you think they will be talking to Capricor? I do!

jimmy667

jimmy667 6月前

You are darn straight. And you have been darn right with CAPR

jimmy667

jimmy667 6月前

I believe Schwab gets paid for order flow so might be harder to get good execution. Fidelity does not and has better execution. Schwab used to have some of the best but I believe that changed a few years ago maybe when they bought TDAmeritrade that sold its order flow. I have accounts at both but do not trade a Schwab much for that reason. I had to switch to Fidelity from TD Ameritrade when Schwab bought them because Schwab did not host some of the types of accounts I have.

Topfuel

Topfuel 6月前

I found my answers on trade halts
https://www.nasdaqtrader.com/Trader.aspx?id=TradingHaltSearch

Capricor Therapeutics

Zr Cpn Ca Nts 21/12/43

iShares S&P 500 Equal We...

Correlate Energy (EM)

Britannia Life Sciences (PK)

Petroteq Energy

Medallion Trust Series 2...

Ionic Brands (EM)

LPKF Laser & Electronics

Canadian Equity Value Po...

Amundi Euro Inflation Ex...

Franklin MSCI Emerging M...

Invesco Markets

WT WTI Crude Oil

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。